Sarepta Therapeutics Valuation
| SRPT Stock | USD 107.95 1.51 1.38% |
At this time, the company appears to be undervalued. Sarepta Therapeutics has a current Real Value of $124.49 per share. The regular price of the company is $107.95. Our model measures the value of Sarepta Therapeutics from inspecting the company fundamentals such as Return On Equity of 0.12, operating margin of 0.05 %, and Shares Outstanding of 95.52 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Sarepta Therapeutics' valuation include:
Price Book 8.4445 | Enterprise Value | Enterprise Value Ebitda 56.1481 | Price Sales 6.2861 | Forward PE 8.7336 |
Undervalued
Today
Please note that Sarepta Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Sarepta Therapeutics is based on 3 months time horizon. Increasing Sarepta Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Sarepta Therapeutics' intrinsic value may or may not be the same as its current market price of 107.95, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 107.95 | Real 124.49 | Target 184.91 | Hype 107.93 |
The intrinsic value of Sarepta Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sarepta Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sarepta Therapeutics helps investors to forecast how Sarepta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sarepta Therapeutics more accurately as focusing exclusively on Sarepta Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Sarepta Therapeutics' intrinsic value based on its ongoing forecasts of Sarepta Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Sarepta Therapeutics' closest peers.
Sarepta Therapeutics Cash |
|
Sarepta Valuation Trend
Sarepta Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Sarepta Therapeutics' financial worth over time. Using both Sarepta Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Sarepta Revenue by Product
Sarepta Therapeutics Total Value Analysis
Sarepta Therapeutics is at this time projected to have valuation of 10.51 B with market capitalization of 10.31 B, debt of 1.4 B, and cash on hands of 2.07 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Sarepta Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.51 B | 10.31 B | 1.4 B | 2.07 B |
Sarepta Therapeutics Investor Information
About 94.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Sarepta Therapeutics had 1:6 split on the 12th of July 2012. Based on the key indicators related to Sarepta Therapeutics' liquidity, profitability, solvency, and operating efficiency, Sarepta Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Sarepta Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sarepta Therapeutics has an asset utilization ratio of 38.09 percent. This implies that the Company is making $0.38 for each dollar of assets. An increasing asset utilization means that Sarepta Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Sarepta Therapeutics Ownership Allocation
Sarepta Therapeutics shows a total of 95.52 Million outstanding shares. The majority of Sarepta Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sarepta Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sarepta Therapeutics. Please pay attention to any change in the institutional holdings of Sarepta Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sarepta Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.24 B. Net Loss for the year was (535.98 M) with profit before overhead, payroll, taxes, and interest of 609.29 M.About Sarepta Therapeutics Valuation
The stock valuation mechanism determines Sarepta Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Sarepta Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sarepta Therapeutics. We calculate exposure to Sarepta Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sarepta Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.3 B | 1.3 B | |
| Pretax Profit Margin | (0.38) | (0.40) | |
| Operating Profit Margin | (0.19) | (0.20) | |
| Net Loss | (0.39) | (0.41) | |
| Gross Profit Margin | 0.79 | 0.83 |
Sarepta Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Sarepta Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 92.4 M | |
| Forward Price Earnings | 8.7336 |
Sarepta Therapeutics Current Valuation Indicators
Sarepta Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Sarepta Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Sarepta Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Sarepta Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Sarepta Therapeutics' worth.Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.